2,190
Views
23
CrossRef citations to date
0
Altmetric
Brief Report

Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen

, , , , , , , , , , , , & show all
Article: e1011492 | Received 23 Dec 2014, Accepted 21 Jan 2015, Published online: 17 Jun 2015

References

  • Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 2013 13:15; PMID:23882160.
  • Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012 72:1081-1091; PMID:22237626; http://dx.doi.org/10.1158/0008-5472.CAN-11-3722.
  • Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012 482:400-404; PMID:22318521; http://dx.doi.org/10.1038/nature10755.
  • Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014 515:577-581; PMID:25428507; http://dx.doi.org/10.1038/nature13988.
  • Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014 371:2189-2199; PMID:25409260; http://dx.doi.org/10.1056/NEJMoa1406498.
  • Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014 344:641-645; PMID:24812403; http://dx.doi.org/10.1126/science.1251102.
  • Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, Castellarin M, Twumasi-Boateng K, Watson PH, Holt RA, et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res 2014 20:1125-1134; PMID:24323902; http://dx.doi.org/10.1158/1078-0432.CCR-13-2147.
  • Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, Zhang W, Sougnez C, Cibulskis K, Sidney J, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014 124:453-462; PMID:24891321; http://dx.doi.org/10.1182/blood-2014-04-567933.
  • Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992 52:881-886; PMID:1459729; http://dx.doi.org/10.1002/ijc.2910520609.
  • Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, Robinson BW, Scott B. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 1999 162:5838-5845; PMID:10229818.
  • Chen W, Anton LC, Bennink JR, Yewdell JW. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 2000 12:83-93; PMID:10661408; http://dx.doi.org/10.1016/S1074-76130080161-2.
  • Anyaegbu CC, Lake RA, Heel K, Robinson BW, Fisher SA. Chemotherapy enhances cross-presentation of nuclear tumor antigens. PLoS One 2014 9:e107894; PMID:25243472; http://dx.doi.org/10.1371/journal.pone.0107894.
  • Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 2004 173:5923-5928; PMID:15528325; http://dx.doi.org/10.4049/jimmunol.173.10.5923.
  • Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014 14:135-146; PMID:24457417; http://dx.doi.org/10.1038/nrc3670.
  • Rosenberg SA, Kawakami Y, Robbins PF, Wang R. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv Cancer Res 1996 70:145-177; PMID:8902056; http://dx.doi.org/10.1016/S0065-230X0860874-X.
  • Kvistborg P, van Buuren MM, Schumacher TN. Human cancer regression antigens. Curr Opin Immunol 2013 25:284-290; PMID:23566921; http://dx.doi.org/10.1016/j.coi.2013.03.005.
  • Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res 2014 2:522-529; PMID:24894089; http://dx.doi.org/10.1158/2326-6066.CIR-13-0227.
  • Westcott PM, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM, Delrosario R, Jen KY, Gurley KE, Kemp CJ, et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 2015; 517:489-92; PMID:25363767.
  • Duncan AM, Ozawa T, Suzuki H, Rozen R. Assignment of the gene for the core protein II UQCRC2 subunit of the mitochondrial cytochrome bc1 complex to human chromosome 16p12. Genomics 1993 18:455-456; PMID:8288258; http://dx.doi.org/10.1006/geno.1993.1500.
  • Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B. Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 2000 165:6047-6055; PMID:11086036; http://dx.doi.org/10.4049/jimmunol.165.11.6047.
  • McDonnell AM, Currie AJ, Brown M, Kania K, Wylie B, Cleaver A, Lake R, Robinson BW. Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation. Oncoimmunology 2012 1:840-846; PMID:23162751; http://dx.doi.org/10.4161/onci.20493.
  • Bundell CS, Jackaman C, Suhrbier A, Robinson BW, Nelson DJ. Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors. Cancer Immunol Immunother 2006 55:933-947; PMID:16283304; http://dx.doi.org/10.1007/s00262-005-0086-6.
  • Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003 63:4490-4496; PMID:12907622.
  • Nelson DJ, Mukherjee S, Bundell C, Fisher S, van Hagen D, Robinson B. Tumor progression despite efficient tumor antigen cross-presentation and effective “arming” of tumor antigen-specific CTL. J Immunol 2001 166:5557-5566; PMID:11313395; http://dx.doi.org/10.4049/jimmunol.166.9.5557.
  • Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 1999 59:1071-1079; PMID:10070965.
  • Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009 10:R25; PMID:19261174; http://dx.doi.org/10.1186/gb-2009-10-3-r25.
  • Garcia-Alcalde F, Okonechnikov K, Carbonell J, Cruz LM, Götz S, Tarazona S, Dopazo J, Meyer TF, Conesa A. Qualimap: evaluating next-generation sequencing alignment data. Bioinformatics 2012 28:2678-2679; PMID:22914218; http://dx.doi.org/10.1093/bioinformatics/bts503.
  • Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009 25:1754-1760; PMID:19451168; http://dx.doi.org/10.1093/bioinformatics/btp324.
  • Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009 25:2078-2079; PMID:19505943; http://dx.doi.org/10.1093/bioinformatics/btp352.
  • McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010 20:1297-1303; PMID:20644199; http://dx.doi.org/10.1101/gr.107524.110.
  • Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012 22:568-576; PMID:22300766; http://dx.doi.org/10.1101/gr.129684.111.
  • Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010 38:e164; http://dx.doi.org/10.1093/nar/gkq603.
  • Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer IGV: high-performance genomics data visualization and exploration. Brief Bioinform 2013 14:178-192; PMID:22517427; http://dx.doi.org/10.1093/bib/bbs017.
  • Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O, Buus S, Nielsen M. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009 61:1-13; PMID:19002680; http://dx.doi.org/10.1007/s00251-008-0341-z.
  • Hammond T, Lee S, Watson MW, Flexman JP, Cheng W, Price P. Decreased IFNgamma production correlates with diminished production of cytokines by dendritic cells in patients infected with hepatitis C virus and receiving therapy. J Viral Hepat 2011 18:482-492; PMID:20529204; http://dx.doi.org/10.1111/j.1365-2893.2010.01331.x.